Cargando…
MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers
BACKGROUND: Regular ingestion of sub-hallucinogenic doses of psychedelics, referred to as “microdosing”, has gained increasing popularity and attention in the press and in online forums, with reported benefits across multiple cognitive and emotional domains. Rigorously controlled studies to date, ho...
Autores principales: | Murphy, Robin J., Sumner, Rachael L., Evans, William, Menkes, David, Lambrecht, Ingo, Ponton, Rhys, Sundram, Frederick, Hoeh, Nicholas, Ram, Sanya, Reynolds, Lisa, Muthukumaraswamy, Suresh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062934/ https://www.ncbi.nlm.nih.gov/pubmed/33892777 http://dx.doi.org/10.1186/s13063-021-05243-3 |
Ejemplares similares
-
Correction to: MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers
por: Murphy, Robin J., et al.
Publicado: (2021) -
An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)
por: Donegan, Carina Joy, et al.
Publicado: (2023) -
A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder
por: Plank, Julia R., et al.
Publicado: (2022) -
The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial
por: Yanakieva, Steliana, et al.
Publicado: (2018) -
A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4–6 μg/kg) in patients with major depressive disorder
por: Chen, Joseph C. C., et al.
Publicado: (2020)